Biopure Corp. , the ambitious Cambridge biotech firm that was working on developing a human blood substitute, has run out of time and money. The company said it filed for Chapter 11 bankruptcy protection and will sell most of its remaining assets to OPK Biotech LLC, a Delaware company. (Full article: 474 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
